Real-world comparative effectiveness of tofacitinib, tumour necrosis factor inhibitors, and interleukin 17 inhibitors among patients with axial spondylarthritis and psoriatic arthritisFirst published 15/11/2024 Last updated 18/02/2025 EU PAS number: EUPAS1000000226StudyOngoing